ZIDOVUDINE

Post-LOE

zidovudine

Hikma

ANDAORALTABLET

Approved

Sep 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZIDOVUDINE (zidovudine) by Hikma is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2005.

Drug data last refreshed 18h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT00000965N/ACompleted

The Effects of Zidovudine on the Blood of HIV-Infected Patients

20 enrolled

HIV Infections

NCT00001075N/ACompleted

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

55 enrolled

HIV Infections

NCT00000628Phase 1Completed

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

27 enrolled

HIV Infections

NCT00001066Phase 2Completed

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

740 enrolled

HIV Infections

NCT00000999Phase 1Completed

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

500 enrolled

HIV Infections

Worked on ZIDOVUDINE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.